Insider · CIK 0001277495

BOESS CARSTEN

Reports to the SEC for 8 companies · CRANBURY, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001277495

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+64.9K sh	—	—	64,860
2026-06-18	RCKTROCKET PHARMACEUTICALS, INC.A Award	Director	AAward	+22.9K sh	—	—	52,862
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−22K sh	—	—	0
2026-02-27	RNAAtrium Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−13.5K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−22K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−6,692 sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.9K sh	—	—	0
2025-06-18	RCKTROCKET PHARMACEUTICALS, INC.A Award	Director	AAward	+30K sh	—	—	30,000
2025-06-10	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,034
2025-06-10	RNAMAvidity Biosciences, Inc.A Award	Director	AAward	+6,692 sh	—	—	6,692
2024-06-13	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+13.5K sh	—	—	13,489
2024-06-13	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+23.9K sh	—	—	23,944
2023-06-22	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+25.9K sh	—	—	25,850
2023-06-15	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2022-06-15	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2022-06-13	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+47.7K sh	—	—	47,745
2021-06-16	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2021-06-14	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+12.2K sh	—	—	12,236
2020-06-16	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-01-28	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Class B Common SharesC Conversion	10% Owner	CConversion	+107K sh	—	—	473,035
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Series C Preferred SharesC Conversion	10% Owner	CConversion	−6,392 sh	—	—	0
2018-05-29	KNSAKiniksa Pharmaceuticals International, plc · Series A Preferred SharesC Conversion	10% Owner	CConversion	−107K sh	—	—	0
2018-05-29	KNSAKiniksa Pharmaceuticals International, plcC Conversion	10% Owner	CConversion	+6,392 sh	—	—	79,589
2018-03-29	RCKTROCKET PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2018-02-09	KNSAKiniksa Pharmaceuticals International, plc · Series C Preferred SharesP Purchase	10% Owner	PPurchase	+6,392 sh	$15.64	+$100K	6,392
2017-06-20	RCKTROCKET PHARMACEUTICALS, INC. · Stock Options (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2016-06-23	RCKTROCKET PHARMACEUTICALS, INC. · Stock Options (Right to Buy)A Award	Director	AAward	+12K sh	—	—	12,000
2016-01-11	RCKTROCKET PHARMACEUTICALS, INC. · Stock Options (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2015-06-22	SYNAGEVA BIOPHARMA CORPStock Options (Right to Buy)D Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−40K sh	—	—	0
2015-06-22	SYNAGEVA BIOPHARMA CORPStock Options (Right to Buy)D Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−15.9K sh	—	—	0
2015-06-22	SYNAGEVA BIOPHARMA CORPStock Options (Right to Buy)D Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−45K sh	—	—	0
2015-06-22	SYNAGEVA BIOPHARMA CORPStock Options (Right to Buy)D Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−7,292 sh	—	—	0
2015-06-22	SYNAGEVA BIOPHARMA CORPStock Options (Right to Buy)D Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−9,929 sh	—	—	0
2015-06-22	SYNAGEVA BIOPHARMA CORPD Disposition to Issuer	SVP, Chief Financial Officer	DDisposition to Issuer	−24K sh	—	—	0
2015-06-05	SYNAGEVA BIOPHARMA CORPA Award	SVP, Chief Financial Officer	AAward	+24K sh	—	—	24,000
2015-02-17	SYNAGEVA BIOPHARMA CORPStock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	−29.1K sh	—	—	15,938
2015-02-17	SYNAGEVA BIOPHARMA CORPStock Option (Right to Buy)M Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	−13.2K sh	—	—	9,929
2015-02-17	SYNAGEVA BIOPHARMA CORPS Sale	SVP, Chief Financial Officer	SSale	−1,842 sh	$101.69	−$187K	0
2015-02-17	SYNAGEVA BIOPHARMA CORPS Sale	SVP, Chief Financial Officer	SSale	−16.7K sh	$100.74	−$1.68M	1,842
2015-02-17	SYNAGEVA BIOPHARMA CORPS Sale	SVP, Chief Financial Officer	SSale	−14.8K sh	$99.97	−$1.47M	18,558
2015-02-17	SYNAGEVA BIOPHARMA CORPS Sale	SVP, Chief Financial Officer	SSale	−8,989 sh	$98.85	−$889K	33,308
2015-02-17	SYNAGEVA BIOPHARMA CORPM Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	+29.1K sh	$40.74	+$1.18M	42,297
2015-02-17	SYNAGEVA BIOPHARMA CORPM Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	+13.2K sh	$1.70	+$22.5K	13,235
2014-10-30	SYNAGEVA BIOPHARMA CORPS Sale	SVP, Chief Financial Officer	SSale	−22.9K sh	$80.11	−$1.83M	0
2014-10-30	SYNAGEVA BIOPHARMA CORPM Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	+7,854 sh	$23.00	+$181K	22,904
2014-10-30	SYNAGEVA BIOPHARMA CORPM Exercise/Conversion	SVP, Chief Financial Officer	MExercise/Conversion	+15.1K sh	$1.70	+$25.6K	15,050

Recent filings

Accepted (ET)
Jul 64
BOESS CARSTEN0001140361-26-027676
SEC(opens sec.gov)
Mar 24
BOESS CARSTEN0001193125-26-085921
SEC(opens sec.gov)
Feb 274
BOESS CARSTEN0001193125-26-082132
SEC(opens sec.gov)
Jul 184
BOESS CARSTEN0001140361-25-026406
SEC(opens sec.gov)
Jun 124
BOESS CARSTEN0001599901-25-000127
SEC(opens sec.gov)
Jun 204
BOESS CARSTEN0001140361-24-030723
SEC(opens sec.gov)
Jun 144
BOESS CARSTEN0001599901-24-000095
SEC(opens sec.gov)
Jun 264
BOESS CARSTEN0001140361-23-031528
SEC(opens sec.gov)
Jun 204
BOESS CARSTEN0001599901-23-000044
SEC(opens sec.gov)
Jun 174
BOESS CARSTEN0001209191-22-038216
SEC(opens sec.gov)
Jun 154
BOESS CARSTEN0001140361-22-023145
SEC(opens sec.gov)
Jun 164
BOESS CARSTEN0001209191-21-041132
SEC(opens sec.gov)

Companies

Address

C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE

CRANBURY, NJ, 08512